Dual membrane receptor degradation via folate receptor targeting chimera
10.0
来源：
Nature
关键字：
BISPECIFIC
发布时间：
2025-10-02 23:52
摘要：
The research introduces the FolTAC-dual platform, a novel approach for dual membrane receptor degradation targeting EGFR and HER2, aimed at overcoming drug resistance in HER2-positive breast cancer. The study reports significant therapeutic efficacy in resistant cancer models, with a notable reduction in tumor growth and low toxicity in normal cells. Mechanistic insights reveal enhanced degradation efficiency and potential for clinical translation, positioning FolTAC-dual as a promising candidate for next-generation targeted therapies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0
business_impact
1.0分+1.0
scientific_rigor
1.5分+1.5
timeliness_innovation
1.5分+1.5
investment_perspective
2.5分+2.5
market_value_relevance
1.0分+1.0
team_institution_background
0.5分+0.5
technical_barrier_competition
1.0分+1.0
关键证据
The study demonstrates a significant increase in degradation efficiency of EGFR and HER2.
FolTAC-dual effectively suppresses tumor growth in resistant cancer models.
The platform shows low toxicity in normal cells, indicating its potential for clinical application.
真实性检查
否
AI评分总结
The research introduces the FolTAC-dual platform, a novel approach for dual membrane receptor degradation targeting EGFR and HER2, aimed at overcoming drug resistance in HER2-positive breast cancer. The study reports significant therapeutic efficacy in resistant cancer models, with a notable reduction in tumor growth and low toxicity in normal cells. Mechanistic insights reveal enhanced degradation efficiency and potential for clinical translation, positioning FolTAC-dual as a promising candidate for next-generation targeted therapies.